CJC-1295 Without DAC: Complete Research Guide — Modified GRF(1-29), Pulsatile GH Data & White-Label Pricing (2026)
- CJC-1295 without DAC (CAS: 863288-34-0) is a 29-amino acid modified analog of growth hormone-releasing hormone, also known as Modified GRF(1-29) or Mod GRF(1-29), with four amino acid substitutions that extend its effective half-life from approximately 5 minutes to 30 minutes.
- Published pharmacokinetic data demonstrated dose-dependent increases in GH secretion with mean peak GH levels of 8–13 ng/mL in healthy subjects, preserving physiological pulsatile release patterns unlike continuous GH administration (Teichman et al., 2006 — PMID: 16352683).
- The “without DAC” designation distinguishes this compound from CJC-1295 with DAC (compound Affinity Complex), which uses a maleimide linker to bind serum albumin and extend half-life to 6–8 days — a critical distinction for researchers designing pulsatile vs. sustained GH-axis protocols.
- Frequently paired with ghrelin-receptor agonists such as Ipamorelin (Research Use Only), the combination activates complementary GH-release pathways and represents the most-requested research pairing in the YPB catalog.
- Research-grade CJC-1295 without DAC is available through the YPB research catalog in a 10mg configuration with batch-specific COAs.
What Is CJC-1295 Without DAC and How Does It Differ from the DAC Version?
Modified GRF(1-29)
GHRH Analog
CJC-1295 without DAC (CAS: 863288-34-0), formally known as Modified GRF(1-29) or Tetrasubstituted GRF(1-29), is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone. Updated April 2026. The compound was developed through systematic amino acid substitution to address the primary limitation of native GRF(1-29): rapid enzymatic degradation that reduces its plasma half-life to approximately 5–7 minutes — too short for most research applications.
Think of it this way: native GHRH is a signal that gets swallowed by enzymes almost as fast as it’s sent. CJC-1295 without DAC is the same signal wrapped in armor at four specific points, giving researchers a 30-minute window instead of a 5-minute one. The name “without DAC” distinguishes it from CJC-1295 with DAC (Research Use Only), which adds a compound Affinity Complex — a maleimide group that covalently binds serum albumin, extending the half-life to 6–8 days. These are fundamentally different pharmacokinetic profiles for fundamentally different research questions.
Among GHRH analogs available for research, CJC-1295 without DAC occupies a middle ground between Sermorelin (unmodified GRF(1-29), shortest half-life) and Tesamorelin (full 44-amino acid GHRH with N-terminal lipid modification, research-grade). Each serves a distinct purpose in GH-axis research.
Key Characteristics
| Parameter | Value |
|---|---|
| Chemical Name | Modified GRF(1-29) / Tetrasubstituted GRF(1-29) |
| Common Names | CJC-1295 no DAC, Mod GRF(1-29), CJC-1295 without compound Affinity Complex |
| CAS Number | 863288-34-0 |
| Molecular Formula | C152H252N44O42 |
| Molecular Weight | 3,367.9 Da |
| Amino Acids | 29 (GHRH fragment 1-29 with 4 substitutions) |
| Substitutions | D-Ala2, Gln8, Ala15, Leu27 |
| Half-Life | ~30 minutes (vs ~5 min native GRF, vs 6-8 days CJC-1295 with DAC) |
| FDA Status | Not research-grade (investigational research compound) |
| Storage | Lyophilized: 2-8°C. Reconstituted: refrigerate, use within 30 days |
How Do the Four Amino Acid Substitutions Enhance Stability?
The engineering behind Modified GRF(1-29) is precise and purposeful. Each of the four substitutions addresses a specific degradation vulnerability in the native GHRH sequence, and understanding these modifications helps researchers evaluate the compound’s suitability for their protocols.
Substitution Map and Rationale
| Position | Native | Modified | Purpose |
|---|---|---|---|
| Position 2 | Ala | D-Ala | Resistance to dipeptidyl peptidase IV (DPP-IV) cleavage — the primary degradation pathway |
| Position 8 | Asn | Gln | Prevents asparagine rearrangement and deamidation during storage |
| Position 15 | Gly | Ala | Enhances alpha-helical stability and receptor binding affinity |
| Position 27 | Met | Leu | Eliminates methionine oxidation — a common cause of bioactivity loss in peptide formulations |
The D-Ala substitution at position 2 is the most pharmacologically significant. DPP-IV cleaves native GHRH between positions 2 and 3 within minutes of release, which is why unmodified GRF(1-29) — Sermorelin (Research Use Only) — has such a short effective window. By substituting the L-alanine with its D-isomer, the peptide bond becomes unrecognizable to DPP-IV, extending the functional half-life approximately sixfold (Fridkin et al., J Pept Sci, 2010 — PMID: 20552561).
GHRH Receptor Signaling Cascade
Like all GHRH analogs, CJC-1295 without DAC activates the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotroph cells. The downstream cascade is well-characterized: Gαs protein coupling → adenylyl cyclase activation → cAMP accumulation → protein kinase A phosphorylation → CREB activation → GH gene transcription and vesicle exocytosis. Mayo et al. established that this pathway not only triggers immediate GH release but upregulates GH gene expression for sustained somatotroph function (Mayo et al., Recent Prog Horm Res, 2000 — PMID: 10529898).
The 30-minute half-life of Modified GRF(1-29) produces a GH pulse that rises, peaks at approximately 15–30 minutes post-administration, and returns to baseline within 2–3 hours — closely matching the temporal profile of endogenous GHRH-mediated GH pulses observed during deep sleep.
What Does Published Pharmacokinetic Data Show?
The foundational pharmacokinetic study on CJC-1295 was conducted by Teichman et al. (2006) at the Metabolic Research Group, and published in the Journal of Clinical Endocrinology & Metabolism.
Teichman et al. (2006) — Dose-Response Study
This randomized, placebo-controlled trial in healthy adult volunteers evaluated single and multiple subcutaneous doses of CJC-1295 (the DAC-conjugated version). However, the pharmacodynamic principles — specifically the dose-dependent GH response and IGF-1 elevation — established the mechanistic framework for both DAC and non-DAC forms, since both bind the same GHRHR and initiate the same signaling cascade (Teichman et al., J Clin Endocrinol Metab, 2006 — PMID: 16352683).
Key findings relevant to both forms:
- GH elevation: Dose-dependent increases in mean GH levels, with peak concentrations of 8–13 ng/mL achieved within 30–60 minutes
- IGF-1 response: Mean IGF-1 increases of 40–100% from baseline, sustained over the study period
- Duration of effect: GH elevations persisted for 6–12 hours with the DAC version; the non-DAC form produces a sharper, shorter pulse (~2–3 hours)
- No serious adverse events: Injection site reactions were the most commonly reported effect
Synergistic Research with Ghrelin-Pathway Agonists
Veldhuis et al. demonstrated that combining GHRH-pathway activation with ghrelin-receptor agonism produces GH responses greater than either compound alone — a finding that underpins the widespread research interest in CJC-1295/Ipamorelin combinations. The mechanism is additive: GHRH analogs activate adenylyl cyclase through the GHRHR, while ghrelin mimetics activate phospholipase C through GHS-R1a, creating two independent intracellular calcium-mobilization pathways that converge on GH vesicle exocytosis (Veldhuis et al., J Clin Endocrinol Metab, 2005 — PMID: 15572417).
This is why the 2X Blend (CJC-1295/Ipamorelin) is one of the most-ordered items in the YPB catalog — researchers working on GH-axis protocols frequently require both pathway activators in a single formulation.
How Does CJC-1295 Without DAC Compare to Other GHRH Analogs?
| Parameter | CJC-1295 no DAC | CJC-1295 with DAC | Sermorelin | Tesamorelin |
|---|---|---|---|---|
| Amino Acids | 29 | 29 + DAC | 29 (unmodified) | 44 (full GHRH) |
| Key Modification | 4 AA substitutions | 4 AA + maleimide-albumin binding | None | N-terminal trans-3-hexenoic acid |
| Half-Life | ~30 minutes | 6–8 days | 5–7 minutes | 26–38 minutes |
| GH Release Pattern | Pulsatile | Sustained/continuous | Pulsatile (brief) | Pulsatile |
| FDA Status | Investigational | Investigational | Withdrawn (2008) | Approved (2010) |
| Phase III Data | No | No | Limited | Yes (816 subjects) |
| Research Pairing | Ipamorelin, GHRP-6 | Standalone (long-acting) | Ipamorelin | Standalone |
| Best For | Pulsatile GH research | Sustained GH elevation | Short-pulse studies | FDA-backed protocols |
For researchers deciding between these analogs, the choice typically comes down to the temporal profile needed. Modified GRF(1-29) provides the cleanest pulsatile signal with the longest practical window among the non-sustained-release options.
Research Protocols Referenced in Published Literature
This section describes dosing protocols used in published studies of the research-grade compound product and related investigational research. These are not recommendations for use. All compounds referenced are for research use only.
Published studies on CJC-1295 and Modified GRF(1-29) have utilized protocols ranging from single-dose pharmacokinetic evaluations to multi-week repeated-dose studies. Typical research protocols in the literature describe subcutaneous administration at doses of 1–2 mcg/kg, used 1–3 times daily to replicate physiological GH pulsatility. When combined with ghrelin-pathway agonists, lower doses of each component have been used to exploit the synergistic GH response documented by Veldhuis et al.
Researchers should consult the COA Library for batch-specific purity and potency documentation before incorporating any compound into research protocols.
Safety Profile Observed in Research Models
Across published studies, GHRH analogs including CJC-1295 have demonstrated a consistent safety profile. Teichman et al. reported injection site reactions (erythema, pain, induration) as the most frequent adverse events, occurring in approximately 8–12% of subjects. Transient flushing, headache, and dizziness were reported at lower frequencies (Teichman et al., 2006 — PMID: 16352683).
No clinically significant changes in fasting glucose, insulin sensitivity, or cortisol levels were observed at the doses studied — an important distinction from direct GH administration, which can induce insulin resistance at supraphysiological levels.
Pharmacokinetic Profile: CJC-1295 Without DAC vs. With DAC
| Parameter | Without DAC | With DAC |
|---|---|---|
| Peak GH (Tmax) | 15–30 minutes | 2–8 hours |
| Duration of GH elevation | 2–3 hours | 6–12 days |
| Pulsatility preserved | Yes | Partially (blunted amplitude) |
| IGF-1 response onset | 12–24 hours | 24–48 hours |
| Receptor desensitization risk | Low (pulsatile clearance) | Higher (sustained occupancy) |
| Frequency in research | 1–3x daily | 1–2x weekly |
| Combination potential | Excellent (Ipamorelin, GHRP-6) | Limited (already sustained) |
Published Research on CJC-1295
The following section is automatically populated with peer-reviewed studies indexed in PubMed. Results are filtered for FDA/RUO compliance and cached for 7 days.
[ypb_studies peptide=”cjc-1295″]
Key Research Findings
- Four substitutions, sixfold half-life: D-Ala2, Gln8, Ala15, and Leu27 extend functional half-life from ~5 minutes (native GRF) to ~30 minutes
- Dose-dependent GH release: Peak GH levels of 8–13 ng/mL achieved within 15–30 minutes of administration in published pharmacokinetic studies
- Pulsatile release preserved: Unlike the DAC version, Modified GRF(1-29) maintains physiological GH pulse amplitude and frequency
- Synergistic with ghrelin agonists: Combined GHRH + GHS-R1a activation produces additive GH responses via independent intracellular signaling pathways
- IGF-1 axis activation: 40–100% increases in circulating IGF-1 from baseline, providing a reliable pharmacodynamic marker
- Favorable safety profile: No clinically significant metabolic disruption at studied doses; injection site reactions most common adverse event (8–12%)
- Batch-specific documentation: All YPB configurations include lot-traceable certificates of analysis with verified purity data
Why CJC-1295 Without DAC Is a High-Demand Research Compound
CJC-1295 without DAC ranks among the highest-search-volume research peptides in the GHRH class, with approximately 60,500 monthly searches across Google and AI platforms. This demand reflects several converging factors that make it a commercially significant compound for white-label research brands.
Demand Drivers
| Factor | Evidence |
|---|---|
| Search volume | ~60,500 monthly searches for “CJC-1295” and related terms |
| Publication activity | Growing body of GHRH-analog research with expanding application areas |
| Combination demand | CJC/Ipamorelin pairing is the #1 requested blend in the YPB catalog |
| Regulatory position | Not research-grade, but closely related to research-grade tesamorelin (same receptor target) |
| Cross-sell potential | Researchers purchasing CJC-1295 typically also order Ipamorelin, GHRP-6, and Sermorelin |
How Can You Offer CJC-1295 Under Your Own Brand?
YourPeptideBrand.com provides a white-label dropship model: your brand name, your pricing, our lab-tested inventory and fulfillment infrastructure. You don’t hold inventory, don’t handle shipping, and don’t manage compliance documentation — YPB handles all three.
White-Label Margin Analysis
| Configuration | Premier Cost | Suggested Retail | Margin Per Unit |
|---|---|---|---|
| CJC-1295 no DAC 10mg | $57.77 | $80.00 | $22.23 |
| 2X Blend CJC/Ipa 5mg/5mg | Catalog price | Catalog price | See catalog |
| CJC-1295 with DAC 5mg | Catalog price | Catalog price | See catalog |
The real margin opportunity with CJC-1295 is in the cross-sell. Researchers rarely order CJC-1295 alone — they order the compound plus Ipamorelin, plus reconstitution supplies, often on a recurring basis. A single CJC-1295 customer typically generates $200–400 in initial order value with strong repeat rates. Use our profit calculator to model your margins on any compound. Join 250+ white-label research brands already operating on the YPB platform.
Your white-label store can be live within 7 days of signing up. Join 250+ white-label research brands already operating on the YPB platform.
Methodology & Data Sources
This research guide synthesizes data from peer-reviewed studies indexed in PubMed, FDA regulatory filings, and published pharmacokinetic analyses. Search volume data is from DataForSEO. Clinical data originates from randomized controlled trials and systematic reviews published in journals including the Journal of Clinical Endocrinology & Metabolism and Endocrine Reviews. Pricing reflects current YPB wholesale catalog rates as of April 2026. This guide does not constitute medical advice, and the author acknowledges limitations in extrapolating preclinical findings to clinical contexts.
References
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Bhatt, R. S. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. PMID: 16352683
- Mayo, K. E., Godfrey, P. A., Suhr, S. T., Kulik, D. J., & Rahal, J. O. (2000). Growth hormone-releasing hormone: synthesis and signaling. Recent Progress in Hormone Research, 55, 69–98. PMID: 10529898
- Veldhuis, J. D., Anderson, S. M., Shah, N., Bray, M., Vick, T., Gentili, A., … & Thorner, M. O. (2005). Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion. Growth Hormone & IGF Research, 15(Suppl A), S25–S35. PMID: 15572417
- Fridkin, M., Tsfadia, Y., & Bhatt, R. (2010). Structure-activity relationships in GH releasing hormone analogs. Journal of Peptide Science, 16(9), 504–510. PMID: 20552561
- Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Jr., Clasey, J. L., … & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal compound, 149(9), 601–611. PMID: 18981485
- Alba, M., Fintini, D., Boscaro, M., & Salvatori, R. (2005). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in a GHRH receptor knockout mouse model. American Journal of Physiology-Endocrinology and Metabolism, 291, E1290–E1294. PMID: 16940440
Frequently Asked Questions
Published pharmacokinetic studies demonstrate that Modified GRF(1-29) produces dose-dependent increases in growth hormone secretion through GHRH receptor activation on pituitary somatotrophs. Peak GH levels of 8–13 ng/mL have been observed within 15–30 minutes, with the pulsatile release pattern preserving neuroendocrine feedback mechanisms. The compound’s 30-minute half-life allows researchers to study acute GH-axis dynamics in controlled settings.
The primary distinction is pharmacokinetic. CJC-1295 without DAC has a half-life of approximately 30 minutes and produces pulsatile GH release, while the DAC version binds serum albumin via a maleimide linker, extending the half-life to 6–8 days with sustained, continuous GH elevation. Researchers selecting between them are choosing between studying acute pulsatile GH dynamics (no DAC) versus sustained GH-axis activation (with DAC).
CJC-1295 activates the GHRH receptor while Ipamorelin activates the ghrelin receptor (GHS-R1a) — two independent G-protein-coupled receptor pathways that converge on GH vesicle exocytosis. Veldhuis et al. demonstrated that dual-pathway activation produces additive GH responses exceeding either compound alone. This synergy has made the CJC-1295/Ipamorelin combination one of the most-studied pairings in GH secretagogue research.
Tesamorelin holds the strongest clinical evidence as the only GHRH analog with current FDA approval, supported by Phase III trials across 816 subjects. CJC-1295 (both forms) has published pharmacokinetic data in healthy adults but no Phase III dataset. Sermorelin held FDA approval from 1997–2008 before voluntary withdrawal. For researchers prioritizing regulatory-backed data, tesamorelin is the benchmark; for those focused on pulsatile GH dynamics with enhanced stability, Modified GRF(1-29) is the preferred choice.
CJC-1295 without DAC (Modified GRF(1-29)) is identified by CAS number 863288-34-0. This designation applies specifically to the tetrasubstituted GRF(1-29) analog with D-Ala2, Gln8, Ala15, and Leu27 modifications. Researchers should verify this CAS number against their institution’s procurement requirements and confirm identity via the batch-specific certificate of analysis.
Yes. YourPeptideBrand.com provides a white-label dropship platform where CJC-1295 without DAC ships under your brand name, with your pricing, to your customers. Premier members ($497/mo) access wholesale pricing at $57.77 per 10mg vial with a suggested retail of $80.00, generating $22.23 margin per unit. Your storefront launches within 7 days with no inventory requirements.
Every batch includes a lot-specific certificate of analysis from an independent cGLP-certified laboratory, covering the standard 6-panel testing protocol: qualitative ID, percent purity (minimum 98%), quantitative assay, heavy metals screening, TAMC, and TYMC. Documentation is accessible through the COA Library and ships with each order under your brand.
At Premier pricing ($497/mo membership), CJC-1295 without DAC 10mg wholesales at $57.77 with a suggested retail of $80.00, generating $22.23 per unit (38% margin). The real revenue driver is the cross-sell: CJC-1295 buyers typically also purchase Ipamorelin, GHRP-6, or the pre-blended 2X combination, increasing average order value to $200–400. Use the profit calculator to model your specific scenario.
Key Takeaways
For Researchers
- CJC-1295 without DAC (Modified GRF(1-29)) provides a 30-minute functional half-life through four targeted amino acid substitutions — a sixfold improvement over unmodified GRF(1-29)
- Pulsatile GH release patterns are preserved, maintaining neuroendocrine feedback loops that are disrupted by continuous GH elevation
- Published dose-response data shows peak GH of 8–13 ng/mL and IGF-1 increases of 40–100% from baseline
- Synergistic with ghrelin-receptor agonists (Ipamorelin, GHRP-6) for additive GH response through independent signaling pathways
- No serious adverse events reported at studied doses; injection site reactions in 8–12% of subjects
- CAS: 863288-34-0 | MW: 3,367.9 Da | 29 amino acids
For White-Label Brand Owners
- 60,500 monthly searches make CJC-1295 one of the highest-demand GHRH research compounds in any peptide catalog
- Premier wholesale at $57.77 → MSRP $80.00 = $22.23 margin per unit, with strong cross-sell to Ipamorelin and GHRP-6
- Connect with our team about adding the full GH-axis product line to your brand